OKYO · NASDAQ · Biotechnology

OKYO Pharma

Develops urcosimod eye drops for neuropathic corneal pain and anterior-segment eye diseases.

$1.64
After-hours close−0.01 (−0.61%)
At close$1.65(+6.45%)
DateEstimateReportedSurprise
Aug 2026
Jul 2026−$0.08−$0.15−87.5%
Jun 2026−$0.08−$0.04+49.8%
Jan 2026−$0.07−$0.01+85.7%
Jan 2025−$0.08
Aug 2024

The latest year is open to everyone — the 27 quarters behind it read with an account.

Sign in
May 2024
Jan 2024
Oct 2023
Aug 2023
Mar 2023
Dec 2022
Oct 2022
Mar 2022
Sep 2021
Mar 2021
Sep 2020
Mar 2020
Sep 2019
Mar 2019
Sep 2018
Mar 2018
Sep 2017
Mar 2017
Sep 2016
Mar 2016
Sep 2015
Mar 2015
Sep 2014
Mar 2014
Sep 2013
Mar 2013
Sep 2012
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Aug 10, 2026
Jul 20, 2026−$0.08−$0.15−87.5%
Jun 3, 2026−$0.08−$0.04+49.8%
Jan 30, 2026−$0.07−$0.01+85.7%
Jan 29, 2025−$0.08
Aug 13, 2024

The latest year is open to everyone — the 27 quarters behind it read with an account.

Sign in
May 13, 2024
Jan 9, 2024
Oct 1, 2023
Aug 15, 2023
Mar 31, 2023
Dec 30, 2022
Oct 1, 2022
Mar 31, 2022
Sep 30, 2021
Mar 31, 2021
Sep 30, 2020
Mar 31, 2020
Sep 30, 2019
Mar 31, 2019
Sep 30, 2018
Mar 31, 2018
Sep 30, 2017
Mar 31, 2017
Sep 30, 2016
Mar 31, 2016
Sep 30, 2015
Mar 31, 2015
Sep 30, 2014
Mar 31, 2014
Sep 30, 2013
Mar 31, 2013
Sep 30, 2012